ENTA
Enanta Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.08
+0.43%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.9x
Market Cap
$410.09M
MomentumView details →
1D Return
+0.43%
YTD Return
−11.29%
RSI (14)
56.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.9x
Market Cap
$410.09M
RSI (14)
56.1
MomentumView details →
1D Return
+0.43%
YTD Return
−11.29%
SummaryUpdated Jun 1, 2026
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is a biotechnology company founded in 1995 and headquartered in Watertown, Massachusetts. The company specializes in discovering and developing small molecule drugs for treating viral infections and liver diseases. Enanta went public in March 2013 and has established itself as a focused developer of antiviral therapeutics, with a particular emphasis on respiratory viruses and hepatitis treatments. The company operates primarily as a research and development organization, with revenue generated through royalty agreements from previously developed drugs and ongoing clinical development programs.
Similar companies
Latest newsMore news →
Enanta Pharmaceuticals reported a Q3 2026 loss of $0.67 per share, missing the Zacks Consensus Estimate of a loss of $0.37, and compared to a loss of $0.85 per share a year ago.25d agoAbbVie received European Commission approval of MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C virus in the European Union.73d ago